ANI Pharmaceuticals, Inc. (ANIP)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$71.23-1.06%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · ANIP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -40.3% |
| Our one-year growth estimate | diamond | -60.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 19.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 23 industry peers · Company calendar date is not available
ANIP — CEO transition
Dated 2026-08-24
Director — Henry Gosebruch: The filing discloses the appointment of a new director (Henry Gosebruch) and the resignation of another director (Samy Shanmugam) who remains in his executive role, representing a standard board composition change rather than a loss of senior management.
Why it matters: New products in the Generics segment are key for revenue growth. Successful launches show good execution.
Supportive ifAt least 5 new Generics products launched by the end of Q3.
Worry ifFewer than 5 new Generics products launched by the end of Q3.
Why it matters: A share repurchase program shows that management believes in the company's value. It shows their focus on capital use.
Supportive ifANI announces the repurchase of at least $20 million in shares by the end of 2026.
Worry ifANI does not execute any share repurchases by the end of 2026.
Why it matters: Total revenue growth shows how healthy the business is and backs guidance.
Supportive ifTotal net revenue grows above $270 million in Q2 2026.
Worry ifTotal net revenue falls below $250 million in Q2 2026.
Why it matters: An update may show changes in the market or how the product is doing.
Watch forManagement raises total net revenue guidance for 2026 to more than $1,140 million.
Also watch forManagement lowers total net revenue guidance for 2026 to less than $1,080 million.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$136 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $284 loss on $10,000 · 2.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,866 loss on $10,000 · 28.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Growth in this area is key for revenue. It is expected to be 60% of sales.
Supportive ifAnnouncement of new product launches or partnerships in the Rare Disease segment.
Worry ifNo updates or delays in the Rare Disease portfolio expansion plans.
Why it matters: Growth in Cortrophin Gel revenue is important for ANI's long-term plans. A strong performance helps management reach its growth goals.
Supportive ifCortrophin Gel net revenues increase year-over-year by more than 50% in Q3.
Worry ifCortrophin Gel net revenues grow less than 50% year-over-year in Q3.
Why it matters: The share buyback program shows how the company uses its money. It shows care for shareholders.
Watch forManagement says they bought back more than $10 million in shares.
Also watch forNo share repurchase amounts reported in the next quarterly update.
Why it matters: Results from this trial could impact ILUVIEN's market potential and future revenue.
Watch forGood results were shared at a medical conference in Q3 2026.
Also watch forNegative results or delays in announcing the trial results.
Why it matters: Changes in revenue guidance can signal shifts in business performance.
Watch forTotal net revenue guidance is raised above $1,140 million.
Also watch forTotal net revenue guidance is lowered below $1,080 million.
Why it matters: ILUVIEN's lower revenue impacts growth. A recovery would show that management is gaining market share back.
Supportive ifILUVIEN net revenues increase year-over-year by more than 5% in Q3.
Worry ifILUVIEN net revenues decline year-over-year by more than 10% in Q3.
Why it matters: Updates on the share buyback program show management's focus on capital use. This could increase value for shareholders.
Supportive ifAnnouncement of share repurchases totaling at least $10 million by the end of Q3.
Worry ifNo share repurchase announcements by the end of Q3.